🎮 DEMO PLAYGROUND - Sample data for demonstration purposes

MedPoint Clinical Research Network

Clinical Trial Intelligence Platform

Sarah Chen
Network Administrator
SC

APEX-301

PHASE III

Advanced Non-Small Cell Lung Cancer • Apex Therapeutics

ENROLLMENT
64%
287 / 450 patients
BUDGET
60%
$5.1M /$ $8.5M
SCREEN FAILURES
12.8%
vs 15.0% benchmark
ACTIVE SITES
4
11.0 total FTE
MILESTONES
2/5
40% complete
ENROLLMENT TRENDS
BUDGET BREAKDOWN
TOTAL BUDGET
$8.50M
CONSUMED
$5.10M
60%
REMAINING
$3.40M
+3% INF$3.50M
Passthrough
$3.20M (38%)
38%
Investigator Fees
$2.25M (26%)
26%
Consumed
$5.10M (60%)
60%
Remaining
$3.40M (40%)
40%
AVG COST PER PATIENT
$18,888.889
CURRENT BURN RATE
$17,770.035/pt
SITE PERFORMANCE
SITESTATUSENROLLMENTTARGETPROGRESSSCREEN FAILFTE
Nashville
12518069%12.6%4.5
Memphis
8212068%12.8%3
Knoxville
529058%13.3%2
Chattanooga
286047%12.5%1.5
RISK REGISTER
MEDIUM PRIORITY (1)
12
Chattanooga site enrollment velocity below target
P:4 × I:3 • ENROLLMENT
MILESTONES
First Patient Enrolled
Target: 3/20/2024 • Completed: 3/18/2024
50% Enrollment
Target: 3/1/2025 • Completed: 2/28/2025
75% Enrollment
Target: 11/1/2025
Last Patient Enrolled
Target: 3/31/2026
Database Lock
Target: 9/30/2026
TRIAL INFORMATION
Protocol Version:3.1
Sponsor:Apex Therapeutics
CRO:Syneos Health
Therapeutic Area:Oncology
Start Date:3/15/2024
Est. Completion:9/30/2026
Passthrough:$3.20M
Per Patient:$7,111
Investigator Fees:$5,000/pt